Pfizer made one thing clear this week: It's officially back in the obesity race.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.